Compremium Receives FDA Breakthrough Device Designation for Non-Invasive Central Venous Pressure Measurement System and has also joined FDA’s TAP Progr…

Compremium AG today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation to ...
Seeking Alpha

Intelligent Bio Solutions Announces Adoption of its Non-Invasive Drug Screening Solution by Global Engineering Leader, Pyrotek

NEW YORK, Oct. 14, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company offering non-invasive, rapid testing solutions, today ...
Seeking Alpha

Intelligent Bio Solutions Showcases Rapid, Non-Invasive Drug Testing Capabilities in Remote Queensland Workforce Deployment

NEW YORK, May 19, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing ...
Laweekly

Revolutionizing Brain Cancer Treatment: NeOnc Introduces First Non-Invasive Intranasal Drug Delivery for Brain Cancer

NeOnc, a biotech company helmed by Dr. Thomas Chen, brings the first non-invasive intranasal drug delivery for brain cancer into the spotlight. With this revolutionary treatment, NeOnc is poised to ...
Hosted on MSN

How Epinal’s Narcolyzer addresses a growing emergent need for non-invasive, rapid, handheld narcotics testing

Public institutions across the world are reassessing how they identify and respond to narcotic impairment. Courts, transportation agencies, probation departments, and treatment programs are ...
Nasdaq

Intelligent Bio Solutions Inc. Submits FDA 510(k) Application for Intelligent Fingerprinting Drug Screening System

Intelligent Bio Solutions Inc. (INBS) has submitted a 510(k) premarket notification to the FDA for its Intelligent Fingerprinting Drug Screening System, a rapid and non-invasive drug testing method ...
Fox2Now St. Louis

New Drug Application initiated with U.S. FDA for TAR-200, the first and only intravesical drug releasing system for patients with BCG-unresponsive high-risk non-muscle-invasive ...

Application accepted for U.S. FDA Real-Time Oncology Review (RTOR) based on Phase 2b SunRISe-1 study showing highest single-agent complete response rate of 83.5 percent 1 RARITAN, N.J., Jan. 15, 2025 ...
Nasdaq

Intelligent Bio Solutions Showcases Rapid, Non-Invasive Drug Testing Capabilities in Remote Queensland Workforce Deployment

Completion of 160 tests conducted in less than 90 minutes demonstrates a level of speed and efficiency beyond the limits of traditional testing approaches NEW YORK, May 19, 2025 (GLOBE NEWSWIRE) -- ...